russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLCrussjcardiol-3320Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWГетерогенность липопротеидов и их роль в развитии сердечно-сосудистых заболеванийThe heterogeneity of lipoproteins and their role in the development of cardiovascular diseaseshttps://orcid.org/0000-0001-6742-5976УткинаЕ. А.UtkinaE. A.

Уткина Елена Анатольевна — кандидат химических наук, старший научный сотрудник лаборатории проблем атеросклероза Института Экспериментальной Кардиологии.

Москва

Moscow

utkelena@yandex.ruhttps://orcid.org/0000-0001-8909-8662АфанасьеваО. И.AfanasievaO. I.

Афанасьева Ольга Ильинична — доктор биологических наук, ведущий научный сотрудник лаборатории проблем атеросклероза Института Экспериментальной Кардиологии.

Москва

Moscow

afanasieva.cardio@yandex.ruhttps://orcid.org/0000-0001-5944-6427ПокровскийС. Н.PokrovskyS. N.

Покровский Сергей Николаевич — профессор, доктор биологических наук, и.о. руководителя лаборатории проблем атеросклероза Института Экспериментальной Кардиологии.

Москва

Moscow

dr.pokrovsky@mail.ruФГБУ Национальный медицинский исследовательский центр кардиологии Минздрава РоссииРоссияNational Medical Research Center of CardiologyRussian Federation201911062019058289Copyright © Уткина Е.А., Афанасьева О.И., Покровский С.Н., 20192019Уткина Е.А., Афанасьева О.И., Покровский С.Н.Utkina E.A., Afanasieva O.I., Pokrovsky S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/3320

В основу «липидной гипотезы» патогенеза атеросклероза заложены нарушения липидного обмена и, в частности, гиперхолестеринемия. Основными участниками дислипидемии являются липопротеиды различных классов. Несмотря на применение современных гиполипидемических препаратов, резидуальный риск сердечно-сосудистых осложнений у больных с дислипидемиями остается достаточно высоким. Современные биохимические и физико-химические методы позволили продемонстрировать высокую гетерогенность основных классов липопротеидов.

Настоящий обзор посвящен анализу современных представлений о гетерогенности липопротеидов, краткому описанию существующих подходов к классификации подфракций липопротеидов различных классов, методам их разделения, свойствам, а также вкладу отдельных подфракций липопротеидов в развитие атеросклероза.

The lipid hypothesis of atherosclerosis pathogenesis is based on lipid metabolism disorders and, in particular, hypercholesterolemia. The main participants of dyslipidemia are lipoproteins of various classes. Despite the use of modern lipidlowering drugs, the residual risk of cardiovascular complications in patients with dyslipidemia remains quite high. Modern biochemical and physico-chemical methods allowed demonstrating the high heterogeneity of the main classes of lipoproteins.

This review presents the analysis of modern ideas about the heterogeneity of lipoproteins, a brief description of existing approaches to the classification of lipoproteins, methods of their stratification, as well as the contribution of some subfractions of lipoproteins to the development of atherosclerosis.

атеросклерозлипопротеидыподфракции липопротеидовatherosclerosislipoproteinslipoprotein subfractionsReferencesAday AW, Ridker PM. Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. Front Cardiovasc Med. 2019;6:16. doi:10.3389/fcvm.2019.00016.Aday AW, Ridker PM. Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. Front Cardiovasc Med. 2019;6:16. doi:10.3389/fcvm.2019.00016.Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res. 2016;118 (4):547-63. doi:10.1161/CIRCRESAHA.115.306249.Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res. 2016;118 (4):547-63. doi:10.1161/CIRCRESAHA.115.306249.Recommendations for the treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis of the American Heart Association. Arteriosclerosis. 1984;4:443A-68A.Recommendations for the treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis of the American Heart Association. Arteriosclerosis. 1984;4:443A-68A.Hirayama S, Miida T. Small dense LDL: An emerging risk factor for cardiovascular disease. Clin Chim Acta. 2012;414:215-24.Hirayama S, Miida T. Small dense LDL: An emerging risk factor for cardiovascular disease. Clin Chim Acta. 2012;414:215-24.Зубарева М. Ю., Рожкова Т. А., Горнякова Н. Б. и др. Резидуальный (остаточный) риск у больных очень высокого риска с атерогенными дислипидемиями, находящихся на терапии статинами. Проспективное исследование “Кристалл”. Часть 1: цель, задачи, дизайн и исходные характеристики включенных пациентов. Атеросклероз и дислипидемии 2013;1 (10):26-34.Zubareva MY, Rozhkova TA, Gornyakova NB et al. Residual risk in patients treated with statins from the very hight risk group of the development atherogenic dyslipidemia. A prospective study CRISTALL part 1: purpose, objectives, design, and baseline characteristics of the included patients. The Journal of Atherosclerosis and Dyslipidemias. 2013; 1 (10):26-34. (In Russ.)Nordestgaard BG, Langsted A. Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57 (11):1953-75. doi:10.1194/jlr.R071233.Nordestgaard BG, Langsted A. Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57 (11):1953-75. doi:10.1194/jlr.R071233.Cooney MT, Dudina A, De Bacquer D, et al. How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators. Eur J Cardiovasc Prev Rehabil. 2009;16 (3):304-14. doi:10.1097/HJR.0b013e3283213140.Cooney MT, Dudina A, De Bacquer D, et al. How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators. Eur J Cardiovasc Prev Rehabil. 2009;16 (3):304-14. doi:10.1097/HJR.0b013e3283213140.Carnuta MG, Stancu CS, Toma L. et al. Dysfunctional high-density lipoproteins have distinct composition, diminished anti-inflammatory potential and discriminate acute coronary syndrome from stable coronary artery disease patients. Scientific reports. 2017;7:7295. doi:10.1038/s41598-017-07821-5.Carnuta MG, Stancu CS, Toma L. et al. Dysfunctional high-density lipoproteins have distinct composition, diminished anti-inflammatory potential and discriminate acute coronary syndrome from stable coronary artery disease patients. Scientific reports. 2017;7:7295. doi:10.1038/s41598-017-07821-5.Chung M, Lichtenstein AH, Ip S, et al. Comparability of methods for LDL subfraction determination: A systematic review. Atherosclerosis. 2009;205 (2):342-8. doi:101016/j.atherosclerosis.200812.011.Chung M, Lichtenstein AH, Ip S, et al. Comparability of methods for LDL subfraction determination: A systematic review. Atherosclerosis. 2009;205 (2):342-8. doi:101016/j.atherosclerosis.200812.011.Pownall HJ, Gotto AM. Human Plasma Lipoprotein metabolism. In: Ballantyne CM, ed. Clinical Lipidology: A Companion to Braunwald's Heart Disease. 1st ed. Saunders. 2009:1-10.Pownall HJ, Gotto AM. Human Plasma Lipoprotein metabolism. In: Ballantyne CM, ed. Clinical Lipidology: A Companion to Braunwald's Heart Disease. 1st ed. Saunders. 2009:1-10.Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol. 2003;6 (4):179-88.Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol. 2003;6 (4):179-88.Campos H, Blijlevens E, McNamara JR, et al. LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb. 1992;12 (12):1410-9.Campos H, Blijlevens E, McNamara JR, et al. LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb. 1992;12 (12):1410-9.Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab. 2002;48 (3-4):171-80.Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab. 2002;48 (3-4):171-80.Уткина Е. А., Афанасьева О. И., Ежов М. В. и др. Связь различных подфракций липопротеидов с коронарным атеросклерозом у мужчин среднего возраста, получавших терапию статинами. Кардиологический вестник. 2014;9 (1):68-76.Utkina EA, Afanasyeva OI, Ezhov MV et al. Association between different lipoprotein subfractions and coronary atherosclerosis in middle-aged men on statin therapy. Kardiologicheskij Vestnik. 2014;9 (1):68-76. (In Russ.Warnick GR, McNamara JR, Boggess CN, et al. Polyacrylamide gradient gel electrophoresis of lipoprotein subclasses. Clin Lab Med. 2006;26 (4):803-46. doi:10.1016/j.cll.2006.07.005.Warnick GR, McNamara JR, Boggess CN, et al. Polyacrylamide gradient gel electrophoresis of lipoprotein subclasses. Clin Lab Med. 2006;26 (4):803-46. doi:10.1016/j.cll.2006.07.005.Kulkarni KR. Cholesterol profile measurement by vertical auto profile method. Clin Lab Med. 2006;26 (4):787-802. doi:10.1016/j.cll.2006.07.004.Kulkarni KR. Cholesterol profile measurement by vertical auto profile method. Clin Lab Med. 2006;26 (4):787-802. doi:10.1016/j.cll.2006.07.004.Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9 (5):533-71.Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9 (5):533-71.Hoefner DM, Hodel SD, O'Brien JF, et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem. 2001;47 (2):266-74.Hoefner DM, Hodel SD, O'Brien JF, et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem. 2001;47 (2):266-74.Уткина Е. А., Афанасьева О. И., Ежов М. В. и др. Влияние повышенной концентрации Лп(а) на определение подфракций липопротеинов методом нативного электрофореза. Клиническая лабораторная диагностика. 2016;61 (8):461-6.Utkina EA, Afanasieva OI, Ezhov MV, et al. The effect of increased concentration of lipoprotein(a) on identification of sub-faction of lipoproteins using native electrophoresis technique. Clinical Laboratory Diagnostics. 2016;61 (8):461-6. (In Russ.)Aru V, Lamb C, Khakimov B, et al. Quantification of lipoprotein profiles by nuclear magnetic resonance spectroscopy and multivariate data analysis. TrAC Trends in Analytical Chemistry. 2017;94:210-9.Aru V, Lamb C, Khakimov B, et al. Quantification of lipoprotein profiles by nuclear magnetic resonance spectroscopy and multivariate data analysis. TrAC Trends in Analytical Chemistry. 2017;94:210-9.Dallinga-Thie GM, Kroon J, Boren J, Chapman MJ. Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy? Curr Cardiol Rep. 2016;18 (7):67 doi:10.1007/s11886-016-0745-6.Dallinga-Thie GM, Kroon J, Boren J, Chapman MJ. Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy? Curr Cardiol Rep. 2016;18 (7):67 doi:10.1007/s11886-016-0745-6.Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32 (11):1345-61. doi:10.1093/eurheartj/ehr112.Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32 (11):1345-61. doi:10.1093/eurheartj/ehr112.Takahashi S. Triglyceride Rich Lipoprotein -LPL-VLDL Receptor and Lp(a) -VLDL Receptor Pathways for Macrophage Foam Cell Formation. J Atheroscler Thromb. 2017;24 (6):552-9. doi:10.5551/jat.RV17004.Takahashi S. Triglyceride Rich Lipoprotein -LPL-VLDL Receptor and Lp(a) -VLDL Receptor Pathways for Macrophage Foam Cell Formation. J Atheroscler Thromb. 2017;24 (6):552-9. doi:10.5551/jat.RV17004.Taskinen MR, Adiels M, Westerbacka J, et al. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol. 2011;31:2144-50.Taskinen MR, Adiels M, Westerbacka J, et al. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol. 2011;31:2144-50.Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: a new paradigm. Endocr Rev. 2015;36:131-47.Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: a new paradigm. Endocr Rev. 2015;36:131-47.Озерова И. Н., Метельская В. А., Перова Н. В. и др. Связь субфракционного спектра липопротеинов низких плотностей с уровнем триглицеридов в крови при разной степени стенозов коронарных артерий. Атеросклероз и дислипидемии. 2014;2:33-7.Ozerova IN, Metelskaya VA, Perova NV, et al. Relationship of low densities lipoprotein subfractions with triglycerides level in patients with different grade of coronary arteries stenosis. The Journal of Atherosclerosis and Dyslipidemias. 2014;2:33-7. (In Russ.)Srisawasdi P, Vanavanan S, Rochanawutanon M, et al. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations. Clin Biochem. 2013;46 (15):1509-15. doi:10.1016/j.clinbiochem.2013.06.021.Srisawasdi P, Vanavanan S, Rochanawutanon M, et al. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations. Clin Biochem. 2013;46 (15):1509-15. doi:10.1016/j.clinbiochem.2013.06.021.Афанасьева О. И., Уткина Е. А., Артемьева Н. В. и др. Повышенная концентрация липопротеида(а) и наличие подфракций мелких плотных липопротеидов низкой плотности как независимые факторы риска развития ишемической болезни сердца. Кардиология. 2016;56 (6):5-11. doi: 10.18565/cardio.2016.6.5-11.Afanasieva OI, Utkina EA, Artemieva NV, et al. Elevated Lipoprotein(a) Cоcentration and Presence of Subfractions of Small Dense Low Density Lipoproteins as Independent Factors of Risk of Ischemic Heart Disease. Kardiologiia. 2016;56 (6):5-11. doi:10.18565/cardio.2016.6.5-11. (In Russ.) doi: 10.18565/cardio.2016.6.5-11.Уткина Е.А, Афанасьева О. И., Афанасьева М. И. и др. Подфракции атерогенных апоВ-содержащих липопротеидов у пациентов с тяжелой гиперхолестеринемией. Кардиоваскулярная терапия и профилактика. 2017;16 (4):45-9. doi:10.15829/1728-8800-2017-4-45-49.Utkina EA, Afanasieva OI, Afanasieva MI, et al. Subfractions of atherogenic apoB-lipoproteides in patients with severe hypercholesterolemia. Cardiovascular Therapy and Prevention. 2017;16 (4):45-9. (In Russ.) doi:10.15829/1728-8800-2017-4-45-49.Krauss RM, Wojnooski K, Orr J, et al. Changes in lipoprotein subtraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res. 2012;53 (3):540-7 doi:10.1194/jlr.M018010.Krauss RM, Wojnooski K, Orr J, et al. Changes in lipoprotein subtraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res. 2012;53 (3):540-7 doi:10.1194/jlr.M018010.Hoogeveen RC, Gaubatz JW, Sun Wet, al. Small dense low-density lipoprotein-cholesterol concentrations predict risk tor coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014;34 (5): 1069-77. doi:10.1161/ATVBAHA.114.303284.Hoogeveen RC, Gaubatz JW, Sun Wet, al. Small dense low-density lipoprotein-cholesterol concentrations predict risk tor coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014;34 (5): 1069-77. doi:10.1161/ATVBAHA.114.303284.Berneis KK, Krauss RM. Metabolic origins and clinical significance ot LDL heterogeneity. J Lipid Res. 2002;43 (9):1363-79.Berneis KK, Krauss RM. Metabolic origins and clinical significance ot LDL heterogeneity. J Lipid Res. 2002;43 (9):1363-79.Kei AA, Filippatos TD, Tsimihodimos V, et al. A review ot the role ot apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism. 2012;61 (7):906-21. doi:10.1016/j.metabol.2011.12.002.Kei AA, Filippatos TD, Tsimihodimos V, et al. A review ot the role ot apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism. 2012;61 (7):906-21. doi:10.1016/j.metabol.2011.12.002.Соколов Е.И., Перова Н. В., Щукина Г. Н. Мелкие плотные частицы липопротеидов низкой плотности: механизмы образования, атерогенные свойства, возможности изменения их содержания в плазме крови. Кардиология. 2005;10:91-6.Sokolov EI, Perova NV, Shchukina GN. Density Lipoprotein Particles: Mechanisms Ot Formation, Atherogenic Properties, Possibilities ot Moditication Ot Their Content in Blood Plasma. Kardiologiia. 2005;10:91-6. (In Russ.)Sacks FM, Campos H. Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab. 2003;88 (10):4525-32.Sacks FM, Campos H. Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab. 2003;88 (10):4525-32.Myers GL, Christenson RH, Cushman M, et al. NACB LMPG Committee Members, National Academy ot Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers tor primary prevention ot cardiovascular disease. Clin Chem 2009;55:378-84. doi:10.1373/clinchem.2008.115899.Myers GL, Christenson RH, Cushman M, et al. NACB LMPG Committee Members, National Academy ot Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers tor primary prevention ot cardiovascular disease. Clin Chem 2009;55:378-84. doi:10.1373/clinchem.2008.115899.Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines tor the Management ot Dyslipidaemias. Eur Heart J. 2016;37 (39):2999-3058. doi:10.1093/eurheartj/ehw272.Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines tor the Management ot Dyslipidaemias. Eur Heart J. 2016;37 (39):2999-3058. doi:10.1093/eurheartj/ehw272.Kjellmo CA, Hovland A, Lappegard KT. CVD Risk Stratitication in the PCSK9 Era: Is There a Role tor LDL Subtractions? Diseases. 2018;6 (2). pii: E45. doi:10.3390/diseases6020045.Kjellmo CA, Hovland A, Lappegard KT. CVD Risk Stratitication in the PCSK9 Era: Is There a Role tor LDL Subtractions? Diseases. 2018;6 (2). pii: E45. doi:10.3390/diseases6020045.Метельская В. А. Атеросклероз: мультимаркерные диагностические панели. Российский кардиологический журнал. 2018;23 (8):65-72.Metelskaya VA. Multimarker diagnostic panels tor atherosclerosis. Russian Journal ot Cardiology. 2018; 23 (8):65-72. (In Russ.)Camont L, Chapman MJ, Kontush A. Biological activities ot HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med. 2011;17 (10):594-603. doi:10.1016/j.molmed.2011.05.013.Camont L, Chapman MJ, Kontush A. Biological activities ot HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med. 2011;17 (10):594-603. doi:10.1016/j.molmed.2011.05.013.Asztalos BF, Tani M, Schaeter EJ. Metabolic and tunctional relevance ot HDL subspecies. Curr Opin Lipidol. 2011;22 (3):176-85. doi:10.1097/MOL.0b013e3283468061.Asztalos BF, Tani M, Schaeter EJ. Metabolic and tunctional relevance ot HDL subspecies. Curr Opin Lipidol. 2011;22 (3):176-85. doi:10.1097/MOL.0b013e3283468061.Mani P, Rohatgi A. Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Detunct? Curr Atheroscler Rep. 2015;17 (8):43. doi:10.1007/s11883-015-0521-x.Mani P, Rohatgi A. Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Detunct? Curr Atheroscler Rep. 2015;17 (8):43. doi:10.1007/s11883-015-0521-x.Kosmas CE, Martinez I, Sourlas Aet al. High-density lipoprotein (HDL) tunctionality and its relevance to atherosclerotic cardiovascular disease. Drugs Context. 2018;7:212525. doi:10.7573/dic.212525.eCollection 2018.Kosmas CE, Martinez I, Sourlas Aet al. High-density lipoprotein (HDL) tunctionality and its relevance to atherosclerotic cardiovascular disease. Drugs Context. 2018;7:212525. doi:10.7573/dic.212525.eCollection 2018.Krychtiuk KA, Kastl SP, Ptattenberger S. Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease. Atherosclerosis. 2014;237 (2):589-96. doi:10.1016/j.atherosclerosis.2014.10.015.Krychtiuk KA, Kastl SP, Ptattenberger S. Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease. Atherosclerosis. 2014;237 (2):589-96. doi:10.1016/j.atherosclerosis.2014.10.015.Elbaz M, Faccini J, Bongard V. High-density lipoprotein subclass protile and mortality in patients with coronary artery disease: Results trom the GENES study. Arch Cardiovasc Dis. 2016;109 (11):607-17 doi:10.1016/j.acvd.2016.04.007.Elbaz M, Faccini J, Bongard V. High-density lipoprotein subclass protile and mortality in patients with coronary artery disease: Results trom the GENES study. Arch Cardiovasc Dis. 2016;109 (11):607-17 doi:10.1016/j.acvd.2016.04.007.Riwanto M, Rohrer L, von Eckardstein A, Landmesser U. Dystunctional HDL: From Structure-Function-Relationships to Biomarkers. Handb Exp Pharmacol. 2015; 224:33766. doi:10.1007/978-3-319-09665-0_10.Riwanto M, Rohrer L, von Eckardstein A, Landmesser U. Dystunctional HDL: From Structure-Function-Relationships to Biomarkers. Handb Exp Pharmacol. 2015; 224:33766. doi:10.1007/978-3-319-09665-0_10.

The authors declare that there are no conflicts of interest present.